Literature DB >> 18634357

[Influence of controlled hypotensive therapy on renal autoregulation efficiency in the doppler captopril test in patients with chronic glomerulonephritis].

Arkadiusz Lubas1, Grzegorz Zelichowski, Iwona Obroniecka, Zofia Wańkowicz.   

Abstract

UNLABELLED: Regulation of renal vascular resistance is one of main mechanisms of the renal autoregulation. Renal vascular resistance is expressed in the Doppler sonography as a resistance index (RI). AIM OF THE STUDY: Estimation of renal resistance index variability in the Doppler Captopril Test in patients with chronic glomerulonephritis and hypertension in the course of controlled hypotensive therapy.
MATERIAL AND METHODS: 21 patients (13 men + 8 female, age 40 +/- 14.5 years) with chronic glomerulonephritis and hypertension were enrolled to the study. Twice, in about 6 months period of intensive hypotensive treatment, the Doppler Captopril Test was performed and variability of RI (deltaRI) was estimated.
RESULTS: Significant rise of deltaRI 0.11 (-11.86:2.83) vs 1.15 (-3.86:7.11); p < 0.05 was found, after 5.8 +/- 2.4 months of hypotensive therapy, and by preserved renal function.
CONCLUSIONS: Controlled hypotensive therapy significantly improves efficiency of renal vascular autoregulation expressed as the variability of renal resistance index in the Doppler Captopril Test.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18634357

Source DB:  PubMed          Journal:  Pol Merkur Lekarski        ISSN: 1426-9686


  2 in total

1.  Renal vascular response to angiotensin II inhibition in intensive antihypertensive treatment of essential hypertension.

Authors:  Arkadiusz Lubas; Grzegorz Zelichowski; Agnieszka Próchnicka; Magdalena Wiśniewska; Marek Saracyn; Zofia Wańkowicz
Journal:  Arch Med Sci       Date:  2010-09-07       Impact factor: 3.318

2.  Renal autoregulation in medical therapy of renovascular hypertension.

Authors:  Arkadiusz Lubas; Grzegorz Zelichowski; Agnieszka Próchnicka; Magdalena Wiśniewska; Zofia Wańkowicz
Journal:  Arch Med Sci       Date:  2010-12-29       Impact factor: 3.318

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.